格隆汇12月19日丨*ST双成(002693.SZ)在投资者互动平台表示，公司产品注射用胸腺法新、注射用生长 抑素、注射用法莫替丁、注射用盐酸克林霉素、注射用磷酸川芎嗪、醋酸奥曲肽注射液等产品均纳入医 保目录。公司产品注射用紫杉醇（白蛋白结合型）目前没有在国内申报。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司第四季度紫杉醇出口销量多少？公司主要收 入来源有哪几个？ *ST双成（002693.SZ）12月19日在投资者互动平台表示，公司的财务数据会根据规定在定期报告中进 行披露，公司有关信息请以公司披露的公告为准。公司主要收入来源为药品销售收入，主要品种为注射 用胸腺法新、注射用紫杉醇（白蛋白结合型）、注射用生长抑素、注射用比伐芦定、注射用盐酸克林霉 素等。 ...

Core Insights - The National Medical Products Administration (NMPA) has announced the cancellation of 80 drug registration certificates, including loratadine tablets, highlighting a significant regulatory shift in China's pharmaceutical industry [1] - Over the past year, NMPA has canceled a total of 626 drug registration certificates, with 89% of these being voluntarily withdrawn by companies, indicating a trend towards industry consolidation and stricter regulations [1][7] - The cancellation of loratadine tablets reflects a broader issue of overcapacity in China's generic drug market, where competition has intensified significantly [2][5] Industry Trends - The Chinese pharmaceutical industry is undergoing a critical phase characterized by increased regulatory scrutiny, normalization of centralized procurement, and accelerated industry consolidation [1][7] - The era of "approval economy" is ending, leading to a drastic reduction in the survival space for low-quality generic drugs [1][7] - The market for loratadine is dominated by a few key players, with Yangtze River Pharmaceutical holding nearly 60% market share, while over 90 companies struggle for the remaining 25% [6] Company Dynamics - Major international pharmaceutical companies are withdrawing from the Chinese market, as seen with Sanofi and Merck Sharp & Dohme canceling multiple product registrations due to competitive pressures and pricing challenges [8][10] - Local companies are also forced to make tough decisions, with Taicang Pharmaceutical canceling 11 products, including commonly used medications, as a response to the pressures of centralized procurement [11][13] - The case of Hengrui Medicine voluntarily canceling a cancer drug registration signals a strategic shift towards innovation rather than competing in the generic drug space [14]